Dr Byron Arana, Head of Cutaneous Leishmaniasis at the Drugs for Neglected Diseases Initiative (DNDi) presents an overview of the discovery & clinical landscape for cutaneous leishmaniasis.
Recorded at the annual ISNTD d3 conference on drug discovery, development & diagnostics as part of the following session with presentations and a panel discussion Q&A:
ISNTD d3 Focus: leishmaniasis (Full session: • Leishmaniasis drug dis... )
Prof Maria Paola Costi (Drug Discovery and Biotechnology Lab, University of Modena and Reggio Emilia, UNIMORE) - "Visceral leishmaniasis: the discovery & clinical landscape" - • Visceral leishmaniasis...
Dr Fabiana Alves (Head of Visceral Leishmaniasis Clinical Programme, DNDi) - "Current and future perspectives for the development of new treatments for visceral leishmaniasis" - • Current and future per...
Dr Byron Arana (Head of Cutaneous Leishmaniasis, DNDi) - "Cutaneous leishmaniasis: from bench to cure" - • Cutaneous leishmaniasi...
Prof Dolores Carrer (Biophysics and Nanotechnology Lab, INIMEC-CONICET-UNC, Argentina) - "Topical treatments for cutaneous leishmaniasis" - • Topical treatments for...
Recorded online on Feb 24th 2021
www.isntd.org/isntd-d3
Негізгі бет Cutaneous leishmaniasis: from bench to cure (Dr Byron Arana, Head of Cutaneous Leishmaniasis, DNDi)
Пікірлер